Bartlett & CO. Wealth Management LLC Decreases Stake in Solventum Corporation $SOLV

Bartlett & CO. Wealth Management LLC reduced its position in Solventum Corporation (NYSE:SOLV) by 66.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,003 shares of the company’s stock after selling 1,951 shares during the period. Bartlett & CO. Wealth Management LLC’s holdings in Solventum were worth $76,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Independent Franchise Partners LLP boosted its position in Solventum by 263.1% in the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock valued at $442,608,000 after buying an additional 4,217,570 shares during the last quarter. Davis Selected Advisers boosted its position in Solventum by 0.8% in the 1st quarter. Davis Selected Advisers now owns 5,288,138 shares of the company’s stock valued at $402,110,000 after buying an additional 41,524 shares during the last quarter. Boston Partners boosted its position in Solventum by 101.3% in the 1st quarter. Boston Partners now owns 3,361,973 shares of the company’s stock valued at $255,554,000 after buying an additional 1,691,565 shares during the last quarter. Northern Trust Corp lifted its position in shares of Solventum by 3.3% during the first quarter. Northern Trust Corp now owns 1,807,674 shares of the company’s stock worth $137,456,000 after purchasing an additional 58,373 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Solventum by 2.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,173,960 shares of the company’s stock worth $89,268,000 after purchasing an additional 24,762 shares during the last quarter.

Solventum Price Performance

Shares of NYSE:SOLV opened at $74.03 on Friday. The firm’s 50 day moving average is $72.80 and its two-hundred day moving average is $72.21. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $85.92. The firm has a market capitalization of $12.84 billion, a P/E ratio of 34.27, a PEG ratio of 3.03 and a beta of 0.50. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating the consensus estimate of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same quarter last year, the business earned $1.56 earnings per share. Solventum’s revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on SOLV shares. Wells Fargo & Company increased their price target on shares of Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Monday, September 15th. KeyCorp started coverage on shares of Solventum in a research report on Friday, June 6th. They set a “sector weight” rating on the stock. UBS Group started coverage on shares of Solventum in a research report on Wednesday. They set a “neutral” rating and a $77.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Solventum in a research report on Saturday, September 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $94.00 price target (up previously from $87.00) on shares of Solventum in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Solventum has an average rating of “Hold” and an average price target of $84.60.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.